Oculis Holding AG (OCS)
OCS Stock Price Chart
Explore Oculis Holding AG interactive price chart. Choose custom timeframes to analyze OCS price movements and trends.
OCS Company Profile
Discover essential business fundamentals and corporate details for Oculis Holding AG (OCS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 May 2021
Employees
49.00
Website
https://oculis.comCEO
Riad Sherif
Description
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
OCS Financial Timeline
Browse a chronological timeline of Oculis Holding AG corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.48, while revenue estimate is $233.98k.
Earnings released on 11 May 2026
EPS came in at -$0.63 falling short of the estimated -$0.49 by -28.57%, while revenue for the quarter reached $253.19k , missing expectations by -0.24%.
Earnings released on 3 Mar 2026
EPS came in at -$0.51 falling short of the estimated -$0.48 by -6.73%, while revenue for the quarter reached $518.44k , beating expectations by +262.75%.
Earnings released on 10 Nov 2025
EPS came in at -$0.40 surpassing the estimated -$0.50 by +20.00%, while revenue for the quarter reached $305.46k , beating expectations by +123.18%.
Earnings released on 21 Aug 2025
EPS came in at -$0.59 falling short of the estimated -$0.53 by -11.32%, while revenue for the quarter reached $328.48k , beating expectations by +129.16%.
Earnings released on 8 May 2025
EPS came in at -$0.77 falling short of the estimated -$0.51 by -50.98%, while revenue for the quarter reached $321.94k , beating expectations by +47.99%.
Earnings released on 11 Mar 2025
EPS came in at -$0.76 falling short of the estimated -$0.48 by -58.33%, while revenue for the quarter reached $3.30k , missing expectations by -97.71%.
Earnings released on 7 Nov 2024
EPS came in at -$0.55 falling short of the estimated -$0.52 by -5.77%, while revenue for the quarter reached $236.01k , missing expectations by -9.23%.
Earnings released on 27 Aug 2024
EPS came in at -$0.56 falling short of the estimated -$0.43 by -30.23%, while revenue for the quarter reached $273.44k , beating expectations by +0.54%.
Earnings released on 8 May 2024
EPS came in at -$0.44 falling short of the estimated -$0.41 by -7.32%, while revenue for the quarter reached $245.15k , missing expectations by -15.07%.
Earnings released on 18 Mar 2024
EPS came in at -$0.38 surpassing the estimated -$0.42 by +9.52%, while revenue for the quarter reached $216.21k , missing expectations by -23.02%.
Earnings released on 15 Nov 2023
EPS came in at -$0.38 falling short of the estimated -$0.36 by -5.56%, while revenue for the quarter reached $238.78k , beating expectations by +97.45%.
Earnings released on 29 Aug 2023
EPS came in at -$0.38 falling short of the estimated -$0.33 by -15.15%, while revenue for the quarter reached $278.72k , beating expectations by +42.62%.
Earnings released on 31 Mar 2023
EPS came in at -$1.51 , while revenue for the quarter reached $261.36k .
Earnings released on 28 Mar 2023
EPS came in at -$0.30 , while revenue for the quarter reached $231.38k .
Earnings released on 30 Sept 2022
EPS came in at -$0.31 , while revenue for the quarter reached $205.28k .
Earnings released on 30 Jun 2022
EPS came in at -$0.39 , while revenue for the quarter reached $250.53k .
Earnings released on 31 Mar 2022
EPS came in at -$0.32 , while revenue for the quarter reached $267.89k .
Earnings released on 31 Dec 2021
EPS came in at -$0.19 , while revenue for the quarter reached $423.21k .
Earnings released on 30 Sept 2021
EPS came in at -$0.16 , while revenue for the quarter reached $21.48k .
OCS Stock Performance
Access detailed OCS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
